The metabolic syndrome as a link between smoking and cardiovascular disease

Diabetes, Obesity and Metabolism

Volumn 6, Issue 2, 2004, Pages 127-132

  Dzien, A ^a   Dzien Bischinger, C ^b   Hoppichler, F ^c   Lechleitner, Monika ^c  

^a Medical Center Hentschelhof   (Austria)

^b KRANKENHAUS DER BARMHERZIGEN BRÜDER   (Austria)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Insulin resistance; Smoking

Indexed keywords

ACETYLSALICYLIC ACID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; GLUCOSE; INSULIN; PRAVASTATIN; SIBUTRAMINE; SIMVASTATIN; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY FAT; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CIGARETTE SMOKING; CORONARY ARTERY DISEASE; DIET RESTRICTION; DOSE RESPONSE; ELECTROCARDIOGRAPHY; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OUTPATIENT DEPARTMENT; RETROSPECTIVE STUDY; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 1242341221     PISSN: 14628902     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1462-8902.2004.00324.x     Document Type: Article

References (34)

1. Freund KM, Belanger AJ, D'Agostino RB, Kannel WB. The health risks of smoking. The Framingham Study: 34 years of follow-up. Ann Epidemiol 1993; 3: 417-424.
2. Blair SN, Shaten J, Brownell K, Collins G, Lissner L. Body weight change, all-cause mortality, and the cause-specific mortality in the multiple risk factor intervention trial. Ann Intern Med 1993; 119: 749-757.
3. Kim SH, Kim JS, Shin HS, Keen CL. Influence of smoking on markers of oxidative stress and serum mineral concentrations in teenage girls in Korea. Nutrition 2003; 19: 240-243.
4. Keaney JF, Larson MG, Vasan RS et al. Obesity and systemic oxidative stress. Clinical correlates of oxidative stress in the Framingham study. Arterioscler Thromb Vasc Biol 2003; 23: 434-439.
5. de Maat MP, Kluft C. The association between inflammation markers, coronary artery disease and smoking. Vasc Pharmacol 2002; 39: 137-139.
6. Barua RS, Ambrose JA, Saha DC, Eales-Reynolds LJ. Smoking is associated with altered endothelial-derived fibrinolytic and antithrombotic factors: an in vitro demonstration. Circulation 2002; 106: 905-908.
7. Guthikonda S, Sinkey C, Barenz T, Haynes WG. Xanthine oxidase reverses endothelial dysfunction in heavy smokers. Circulation 2003; 107: 416-421.
8. Winkelmann BR, Boehm BO, Nauck M et al. Cigarette smoking is independently associated with markers of endothelial dysfunction and hyperinsulinaemia in non-diabetic individuals with coronary artery disease. Curr Med Res Opin 2001; 17: 132-141.
9. Reaven G, Tsao PS. Insulin resistance and compensatory hyperinsulinemia. The key player between cigarette smoking and cardiovascular disease. J Am Coll Cardiol 2003; 41: 1044-1047.
10. Magis D, Geronooz I, Scheen AJ. Smoking, insulin resistance and type 2 diabetes. Rev Med Liege 2002; 57: 575-581.
11. Tahtinen TM, Vanhala MJ, Oikarinen JA, Keinanen-Kiukaaniemi SM. Effect of smoking on the prevalence-associated cardiovascular risk factors of insulin resistance among Finnish men in military service. J Cardiovasc Risk 1998; 5: 319-323.
12. Reaven G. Metabolic syndrome: pathophysiology and implication for management of cardiovascular disease. Circulation 2002; 106: 286-288.
13. Turner RC, Millns H, Neil HA et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus. United Kingdom Prospective Diabetes Study (UKPDS 23). BMJ 1998; 14: 693-694.
14. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-393.
15. Kong C, Nimm L, Eatrozy T et al. Smoking is associated with increased hepatic lipase activity, insulin resistance, dyslipidaemia and early atherosclerosis in type 2 diabetes. Atherosclerosis 2001; 156: 373-378.
16. Prineas RJ, Crow RS, Blackburn H. The Minnesota Code Manual of Electrocardiographic Finding: Standards and Procedures for Measurement and Classification. Boston: John Wright, PSG, 1982.
17. Langer RD, Knoke JD, Barrett-Connor E. Stability of electrocardiographic classification pre- and postglucose challenge. Am J Epidemiol 2002; 155: 577-584.
18. Reneland R, Alvarez E, Andersson PE, Haenni A, Byberg L, Lithell H. Induction of insulin resistance by beta-blockade but not ACE-inhibition: long-term treatment with atenolol or trandolapril. J Hum Hypertens 2000; 14: 175-180.
19. Lender D, Arauz-Pachello C, Breen L, Mora-Mora P, Ramirez LC, Raskin P. A double blind comparison of the effects of amlodipine and enalapril on insulin sensitivity in hypertensive patients. Am J Hypertens 1999; 12: 298-303.
20. Shiuchi T, Lui TX, Wu L et al. ACE inhibitors improves insulin resistance in diabetic mouse via bradykinin and. Hypertension 2002; 40: 329-334.
21. Facchini F, Hollenbeck CB, Jeppesen J, Chen Y-DI, Reaven GM. Insulin resistance and cigarette smoking. Lancet 1992; 339: 1128-1130.
22. Eliasson B, Attvall S, Taskinen MR, Smith U. Smoking cessation improves insulin sensitivity in healthy middle-aged men. Eur J Clin Invest 1997; 27: 450-456.
23. Wareham NJ, Ness EM, Byrne CD, Cox BD, Day NE, Hales CN. Cigarette smoking is not associated with hyperinsulinemia: evidence against smoking and insulin resistance. Metabolism 1996; 45: 1551-1556.
24. Henkin L, Zaccaro D, Haffner S et al. Cigarette smoking, environmental tobacco smoke and insulin sensitivity: the Insulin Resistance Atherosclerosis Study. Ann Epidemiol 1999; 9: 290-296.
25. Henkin L, Zaccaro D, Haffner S et al. Cigarette smoking, environmental tobacco smoke exposure and insulin sensitivity. The Insulin Resistance Atherosclerosis Study. AEP 1999; 9: 290-296.
26. American Diabetes Association. The prevention and delay of type 2 diabetes. Diabetes Care 2003; 26: S62-S69.
27. Ryan AS. Insulin resistance with aging: effects of diet and exercise. Sport Med 2000; 30: 327-346.
28. Facchini FS, Hua N, Abbasi F, Reaven GM. Insulin resistance as a predictor of age-related diseases. J Clin Endocrinol Metab 2001; 86: 3574-3578.
29. Starr JM, Inch S, Cross S, Deary IJ. Seven-year follow-up of bloos pressure in the healthy old people in Edinburgh (HOPE) cohort. J Hum Hypertens 2000; 14: 773-778.
30. Lakka HM, Lakka TA, Tuomilheto J, Salonen JT. Abdominal obesity is associated with increase risk of acure coronary events in men. Eur Heart J 2002; 23: 706-713.
31. Lithell HO. Insulin resistance and diabetes in the context of treatment of hypertension. Blood Press 1998; (Suppl. 3): 28-31.
32. Costa A, Casamitjana R, Casals E et al. Effects of atorvastatin on glucose homeostasis, postprandial triglyceride response and C-reactive protein in subjects with impaired fasting glucose. Diabet Med 2003; 20: 743-745.
33. Poalisso G, Barbagallo M, Petrella G et al. Effect of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients. Atherosclerosis 2000; 150: 121-127.
34. Hundal RS, Petersen KF, Myerson AB et al. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest 2002; 109: 1321-1326.